Organon (OGN) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]
Organon & Co. (OGN)
Company Research
Source: Yahoo! Finance
The stock fell short of the S&P 500, which registered a loss of 0.63% for the day. On the other hand, the Dow registered a loss of 0.65%, and the technology-centric Nasdaq decreased by 0.47%. The pharmaceutical company's shares have seen a decrease of 8.61% over the last month, not keeping up with the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92%. Investors will be eagerly watching for the performance of Organon in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.93, showcasing a 6.9% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $1.57 billion, showing a 0.63% drop compared to the year-ago quarter. OGN's full-year Zacks Consensus Estimates are calling for earnings of $3.84 per share and revenue of $6.3 billion. These results would represent year-over-year changes of -6.57% and -1.59%, respectively. Investors should also take note of any
Show less
Read more
Impact Snapshot
Event Time:
OGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGN alerts
High impacting Organon & Co. news events
Weekly update
A roundup of the hottest topics
OGN
News
- Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]Yahoo! Finance
- Organon To Present at the Piper Sandler 37th Annual Healthcare ConferenceBusiness Wire
- Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the USPR Newswire
- Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the USBusiness Wire
- Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGNBusiness Wire
OGN
Earnings
- 11/10/25 - Beat
OGN
Sec Filings
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- 11/12/25 - Form 4
- OGN's page on the SEC website